Activation of the Akt-mTOR and MAPK pathways in dedifferentiated liposarcomas

Takeaki Ishii, Kenichi Kouhashi, Kunio Iura, Akira Maekawa, Hirofumi Bekki, Yuichi Yamada, Hidetaka Yamamoto, Kazuki Nabeshima, Hiroyuki Kawashima, Yukihide Iwamoto, Yoshinao Oda

研究成果: ジャーナルへの寄稿記事

5 引用 (Scopus)

抄録

The Akt/mTOR and MAPK pathways play important roles in modulating cellular function in response to extracellular signals, and they are known to be activated in certain kinds of sarcomas. Few investigations have examined these pathways in dedifferentiated liposarcoma (DDLS), in relation to clinicopathological features. Clinicopathological and immunohistochemical analyses were conducted using 99 DDLS specimens. An in vitro study was also conducted to examine the antitumor effects of an mTOR inhibitor and a MEK inhibitor on two DDLS cell lines. The clinicopathological analyses revealed that the AJCC staging was a significant prognostic factor for overall survival and that the tumor size, depth, and location were significant prognostic factors for event-free survival. Phosphorylated Akt (pAkt), pmTOR, pS6RP, p4E-BP1, pMEK, and pERK expressions were positive in 57.4, 52.4, 71.4, 57.1, 84.1, and 50.8 % of the dedifferentiated component of the 63 primary DDLSs. Positive staining for pmTOR was significantly more frequent in the dedifferentiated component than the well-differentiated component. A univariate prognostic analysis revealed that pmTOR expression was associated with poor prognosis in the tumors in the retroperitoneum/ventral body cavity. The mTOR and MEK inhibitors dose-dependently inhibited the cell proliferation of both DDLS cell lines and decreased the expression of downstream pS6RP and pERK, respectively. The combined use of the two inhibitors enhanced antiproliferative activity. In conclusion, the Akt/mTOR and MAPK pathways were activated in DDLS specimens, and the inhibition of these pathways decreased cell proliferation in DDLS cell lines. Our findings suggest that these pathways could be a therapeutic target for patients with DDLS.

元の言語英語
ページ(範囲)4767-4776
ページ数10
ジャーナルTumor Biology
37
発行部数4
DOI
出版物ステータス出版済み - 4 1 2016

Fingerprint

Liposarcoma
Mitogen-Activated Protein Kinase Kinases
Cell Line
Cell Proliferation
Sarcoma
Disease-Free Survival
Neoplasms
Staining and Labeling
Survival

All Science Journal Classification (ASJC) codes

  • Cancer Research

これを引用

Activation of the Akt-mTOR and MAPK pathways in dedifferentiated liposarcomas. / Ishii, Takeaki; Kouhashi, Kenichi; Iura, Kunio; Maekawa, Akira; Bekki, Hirofumi; Yamada, Yuichi; Yamamoto, Hidetaka; Nabeshima, Kazuki; Kawashima, Hiroyuki; Iwamoto, Yukihide; Oda, Yoshinao.

:: Tumor Biology, 巻 37, 番号 4, 01.04.2016, p. 4767-4776.

研究成果: ジャーナルへの寄稿記事

Ishii, T, Kouhashi, K, Iura, K, Maekawa, A, Bekki, H, Yamada, Y, Yamamoto, H, Nabeshima, K, Kawashima, H, Iwamoto, Y & Oda, Y 2016, 'Activation of the Akt-mTOR and MAPK pathways in dedifferentiated liposarcomas', Tumor Biology, 巻. 37, 番号 4, pp. 4767-4776. https://doi.org/10.1007/s13277-015-4232-2
Ishii, Takeaki ; Kouhashi, Kenichi ; Iura, Kunio ; Maekawa, Akira ; Bekki, Hirofumi ; Yamada, Yuichi ; Yamamoto, Hidetaka ; Nabeshima, Kazuki ; Kawashima, Hiroyuki ; Iwamoto, Yukihide ; Oda, Yoshinao. / Activation of the Akt-mTOR and MAPK pathways in dedifferentiated liposarcomas. :: Tumor Biology. 2016 ; 巻 37, 番号 4. pp. 4767-4776.
@article{3a7453012e5b48a9a36ce3c20f1f25f6,
title = "Activation of the Akt-mTOR and MAPK pathways in dedifferentiated liposarcomas",
abstract = "The Akt/mTOR and MAPK pathways play important roles in modulating cellular function in response to extracellular signals, and they are known to be activated in certain kinds of sarcomas. Few investigations have examined these pathways in dedifferentiated liposarcoma (DDLS), in relation to clinicopathological features. Clinicopathological and immunohistochemical analyses were conducted using 99 DDLS specimens. An in vitro study was also conducted to examine the antitumor effects of an mTOR inhibitor and a MEK inhibitor on two DDLS cell lines. The clinicopathological analyses revealed that the AJCC staging was a significant prognostic factor for overall survival and that the tumor size, depth, and location were significant prognostic factors for event-free survival. Phosphorylated Akt (pAkt), pmTOR, pS6RP, p4E-BP1, pMEK, and pERK expressions were positive in 57.4, 52.4, 71.4, 57.1, 84.1, and 50.8 {\%} of the dedifferentiated component of the 63 primary DDLSs. Positive staining for pmTOR was significantly more frequent in the dedifferentiated component than the well-differentiated component. A univariate prognostic analysis revealed that pmTOR expression was associated with poor prognosis in the tumors in the retroperitoneum/ventral body cavity. The mTOR and MEK inhibitors dose-dependently inhibited the cell proliferation of both DDLS cell lines and decreased the expression of downstream pS6RP and pERK, respectively. The combined use of the two inhibitors enhanced antiproliferative activity. In conclusion, the Akt/mTOR and MAPK pathways were activated in DDLS specimens, and the inhibition of these pathways decreased cell proliferation in DDLS cell lines. Our findings suggest that these pathways could be a therapeutic target for patients with DDLS.",
author = "Takeaki Ishii and Kenichi Kouhashi and Kunio Iura and Akira Maekawa and Hirofumi Bekki and Yuichi Yamada and Hidetaka Yamamoto and Kazuki Nabeshima and Hiroyuki Kawashima and Yukihide Iwamoto and Yoshinao Oda",
year = "2016",
month = "4",
day = "1",
doi = "10.1007/s13277-015-4232-2",
language = "English",
volume = "37",
pages = "4767--4776",
journal = "Tumor Biology",
issn = "1010-4283",
publisher = "Springer Netherlands",
number = "4",

}

TY - JOUR

T1 - Activation of the Akt-mTOR and MAPK pathways in dedifferentiated liposarcomas

AU - Ishii, Takeaki

AU - Kouhashi, Kenichi

AU - Iura, Kunio

AU - Maekawa, Akira

AU - Bekki, Hirofumi

AU - Yamada, Yuichi

AU - Yamamoto, Hidetaka

AU - Nabeshima, Kazuki

AU - Kawashima, Hiroyuki

AU - Iwamoto, Yukihide

AU - Oda, Yoshinao

PY - 2016/4/1

Y1 - 2016/4/1

N2 - The Akt/mTOR and MAPK pathways play important roles in modulating cellular function in response to extracellular signals, and they are known to be activated in certain kinds of sarcomas. Few investigations have examined these pathways in dedifferentiated liposarcoma (DDLS), in relation to clinicopathological features. Clinicopathological and immunohistochemical analyses were conducted using 99 DDLS specimens. An in vitro study was also conducted to examine the antitumor effects of an mTOR inhibitor and a MEK inhibitor on two DDLS cell lines. The clinicopathological analyses revealed that the AJCC staging was a significant prognostic factor for overall survival and that the tumor size, depth, and location were significant prognostic factors for event-free survival. Phosphorylated Akt (pAkt), pmTOR, pS6RP, p4E-BP1, pMEK, and pERK expressions were positive in 57.4, 52.4, 71.4, 57.1, 84.1, and 50.8 % of the dedifferentiated component of the 63 primary DDLSs. Positive staining for pmTOR was significantly more frequent in the dedifferentiated component than the well-differentiated component. A univariate prognostic analysis revealed that pmTOR expression was associated with poor prognosis in the tumors in the retroperitoneum/ventral body cavity. The mTOR and MEK inhibitors dose-dependently inhibited the cell proliferation of both DDLS cell lines and decreased the expression of downstream pS6RP and pERK, respectively. The combined use of the two inhibitors enhanced antiproliferative activity. In conclusion, the Akt/mTOR and MAPK pathways were activated in DDLS specimens, and the inhibition of these pathways decreased cell proliferation in DDLS cell lines. Our findings suggest that these pathways could be a therapeutic target for patients with DDLS.

AB - The Akt/mTOR and MAPK pathways play important roles in modulating cellular function in response to extracellular signals, and they are known to be activated in certain kinds of sarcomas. Few investigations have examined these pathways in dedifferentiated liposarcoma (DDLS), in relation to clinicopathological features. Clinicopathological and immunohistochemical analyses were conducted using 99 DDLS specimens. An in vitro study was also conducted to examine the antitumor effects of an mTOR inhibitor and a MEK inhibitor on two DDLS cell lines. The clinicopathological analyses revealed that the AJCC staging was a significant prognostic factor for overall survival and that the tumor size, depth, and location were significant prognostic factors for event-free survival. Phosphorylated Akt (pAkt), pmTOR, pS6RP, p4E-BP1, pMEK, and pERK expressions were positive in 57.4, 52.4, 71.4, 57.1, 84.1, and 50.8 % of the dedifferentiated component of the 63 primary DDLSs. Positive staining for pmTOR was significantly more frequent in the dedifferentiated component than the well-differentiated component. A univariate prognostic analysis revealed that pmTOR expression was associated with poor prognosis in the tumors in the retroperitoneum/ventral body cavity. The mTOR and MEK inhibitors dose-dependently inhibited the cell proliferation of both DDLS cell lines and decreased the expression of downstream pS6RP and pERK, respectively. The combined use of the two inhibitors enhanced antiproliferative activity. In conclusion, the Akt/mTOR and MAPK pathways were activated in DDLS specimens, and the inhibition of these pathways decreased cell proliferation in DDLS cell lines. Our findings suggest that these pathways could be a therapeutic target for patients with DDLS.

UR - http://www.scopus.com/inward/record.url?scp=84945562389&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945562389&partnerID=8YFLogxK

U2 - 10.1007/s13277-015-4232-2

DO - 10.1007/s13277-015-4232-2

M3 - Article

VL - 37

SP - 4767

EP - 4776

JO - Tumor Biology

JF - Tumor Biology

SN - 1010-4283

IS - 4

ER -